Intellia Therapeutics

NTLAsupplier

Intellia Therapeutics is a leading CRISPR gene-editing company developing in vivo therapies that edit genes directly inside the body. Its NTLA-2001 for transthyretin amyloidosis was the first in vivo CRISPR therapy to show clinical proof of concept in humans.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($0.15B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Collaboration & License Revenue (70%)

Grants & Other (30%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

NTLA-2002 (HAE Gene Editing)40%

In vivo CRISPR therapy for hereditary angioedema via liver-targeted gene knockout

NTLA-2001 (ATTR Gene Editing)35%

In vivo CRISPR therapy for transthyretin amyloidosis

Ex Vivo Cell Therapies15%

CRISPR-edited cell therapies for cancer and autoimmune disease

Lieferkettenbeziehungen

Partner

Regeneron Pharmaceuticals

Co-development of ex vivo cell therapies

Auswirkung: Medium — Regeneron partnership for cell therapies

Wettbewerber

Novo Nordisk

Rare blood disorder therapies

Auswirkung: Potential future competition

Pfizer Inc.

Gene therapy approaches

Auswirkung: Competing in genetic medicine pipeline

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Intellia Therapeutics.

Unternehmensinformationen

Hauptsitz

Cambridge, Massachusetts, USA

Gegründet

2014

Mitarbeiter

750+

Website

intelliatx.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten